Generic Name and Formulations:
Amoxicillin, clavulanic acid (as potassium); 250mg/125mg, 500mg/125mg, 875mg/125mg; tabs.
Dr. Reddy's Laboratories, Inc.
Indications for AUGMENTIN:
Susceptible infections including community-acquired pneumonia and acute bacterial sinusitis (see full labeling).
Take with meals. Base dose on amoxicillin component. Due to clavulanic acid component: two 250mg tabs are not equivalent to one 500mg tab; also, the 250mg tab and the 250mg chewable tab are not interchangeable. May use 125mg/5mL or 250mg/5mL susp in place of 500mg tab; or 200mg/5mL or 400mg/5mL susp in place of 875mg tab. Severe infections or respiratory tract infections: 875mg every 12 hrs or 500mg every 8 hrs. Others: 500mg every 12 hrs or 250mg every 8 hrs. Renal impairment: CrCl<30mL/min: do not use 875mg tabs. CrCl: 10–30mL/min: 250–500mg every 12 hrs. CrCl<10mL/min: 250mg–500mg every 24 hrs; hemodialysis: give additional doses during and after dialysis.
Take with meals. Base dose on amoxicillin component. <12 weeks: 30mg/kg/day in 2 divided doses every 12 hrs (use 125mg/5mL). ≥12 weeks: Twice-daily regimen: use 200mg/5mL or 400mg/5mL. Three times daily regimen: use 125mg/5mL or 250mg/5mL. Less severe infections: 25mg/kg/day in 2 divided doses every 12 hrs or 20mg/kg/day in 3 divided doses every 8 hrs. Others: 45mg/kg/day in 2 divided doses every 12 hrs or 40mg/kg/day in 3 divided doses every 8 hrs. ≥40kg: see Adult dose.
History of Augmentin-associated cholestatic jaundice/hepatic dysfunction. XR: Severe renal impairment (CrCl <30mL/min) or hemodialysis.
Cephalosporin, imipenem, or other allergy: not recommended. Monitor blood, renal, and hepatic function in long-term use. Hepatic dysfunction. Mononucleosis. Elderly (consider monitoring renal function). Labor & delivery. Pregnancy (Cat.B). Nursing mothers.
May cause false (+) glucose test with Clinitest, Benedict's or Fehling's soln. Probenecid potentiates amoxicillin. May potentiate oral anticoagulants (monitor). May antagonize oral contraceptives.
Broad-spectrum penicillin + β-lactamase inhibitor.
Diarrhea, nausea, abdominal pain, rash, urticaria, vomiting, vaginitis; anaphylaxis.
XR tabs—28, 40; Tabs 250mg—30; Tabs 500mg, 875mg—20; Susp 125mg/5mL, 250mg/5mL—75mL, 100mL, 150mL; Susp 200mg/5mL, 400mg/5mL—50mL, 75mL, 100mL; Chew tabs 125mg, 250mg—30; Chew tabs 200mg, 400mg—20; Susp ES-600 600mg/5mL—50mL, 75mL, 100mL, 125mL, 150mL, 200mL
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|